This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
CureVac Résultats passés
Passé contrôle des critères 2/6
CureVac a connu une croissance annuelle moyenne de ses bénéfices de 34.1%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 33.8% par an. Les revenus ont augmenté de en hausse à un taux moyen de 45.8% par an. Le rendement des capitaux propres de CureVac est 14.8% et ses marges nettes sont de 182.1%.
Informations clés
34.10%
Taux de croissance des bénéfices
38.24%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 45.76% |
| Rendement des fonds propres | 14.79% |
| Marge nette | 182.11% |
| Dernière mise à jour des bénéfices | 30 Sep 2025 |
Mises à jour récentes des performances passées
Recent updates
Article d’analyse • Jun 15
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise
Despite an already strong run, CureVac N.V. ( NASDAQ:CVAC ) shares have been powering on, with a gain of 50% in the...Article d’analyse • May 27
The Strong Earnings Posted By CureVac (NASDAQ:CVAC) Are A Good Indication Of The Strength Of The Business
CureVac N.V. ( NASDAQ:CVAC ) recently posted some strong earnings, and the market responded positively. We did some...
Nouveau récit • May 06
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement.Article d’analyse • May 01
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth
Those holding CureVac N.V. ( NASDAQ:CVAC ) shares would be relieved that the share price has rebounded 31% in the last...Seeking Alpha • Mar 28
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
Summary CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028. CVAC stock received a boost yesterday after winning a key patent dispute against BioNTech, potentially leading to significant damages if infringement is confirmed in 2025. Despite the legal win, CureVac's pipeline remains weak, with only one wholly-owned asset in clinical development, raising concerns about its long-term viability. Upgrading CureVac stock from "Sell" to "Hold" due to the potential financial windfall from the patent dispute, though fundamental issues remain unresolved. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Summary CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025. Financially strong, with $208.8M in cash plus additional funds of $412.53M from GlaxoSmithKline agreement being redone; the Company believes that it has enough cash on hand to fund operations into 2028. Read the full article on Seeking AlphaArticle d’analyse • Jan 04
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25%
CureVac N.V. ( NASDAQ:CVAC ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Seeking Alpha • Oct 08
CureVac: Back To Square One
Summary Today, we're circling back to a development company called CureVac N.V. The company recently agreed to a deal with GSK plc, that involved a huge upfront payment, as well as potential milestone payouts and royalties. That left CureVac with a huge amount of cash on its balance sheet but pushed its pipeline back to very early-stage development. Read the full article on Seeking AlphaArticle d’analyse • Sep 16
CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk
It's not a stretch to say that CureVac N.V.'s ( NASDAQ:CVAC ) price-to-sales (or "P/S") ratio of 10.6x right now seems...Article d’analyse • Aug 03
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Key Insights The projected fair value for CureVac is US$6.64 based on 2 Stage Free Cash Flow to Equity Current share...Article d’analyse • Jul 05
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Jul 04
CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Summary CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. The mRNA specialist was unable to develop a successful COVID vaccine, unlike rivals Moderna and BioNTech. GSK's $400m purchase of CureVac's infectious disease vaccine candidates, announced yesterday, provides a financial lifeline with milestones, and royalties pledged >$1bn. Despite the deal, CureVac still faces challenges in catching up to competitors like Moderna and BioNTech, making a "sell" recommendation appropriate at this time, in my view. Read the full article on Seeking AlphaArticle d’analyse • Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
CureVac N.V. ( NASDAQ:CVAC ) shareholders would be excited to see that the share price has had a great month, posting a...Article d’analyse • Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Mar 08
CureVac: No Momentum In Sight
Summary CureVac faces challenges as a German court invalidates one of their key mRNA technology patents, raising concerns about their ability to compete in the mRNA space. The invalidated patent relates to an invention that many argue was not a genuine "invention" as the concepts and technologies were already well-known in the scientific community. CureVac's future prospects rely heavily on their partnerships, such as their joint effort with GSK for influenza and COVID vaccines, and their RNA Printer technology for point-of-care production of RNA therapeutics. Read the full article on Seeking AlphaArticle d’analyse • Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...Article d’analyse • Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Key Insights The projected fair value for CureVac is US$19.46 based on 2 Stage Free Cash Flow to Equity CureVac is...Article d’analyse • May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
The latest analyst coverage could presage a bad day for CureVac N.V. ( NASDAQ:CVAC ), with the analysts making...Article d’analyse • Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
The analysts might have been a bit too bullish on CureVac N.V. ( NASDAQ:CVAC ), given that the company fell short of...Article d’analyse • Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Key Insights CureVac's estimated fair value is €15.4 based on 2 Stage Free Cash Flow to Equity Current share price of...Seeking Alpha • Aug 18
CureVac BV reports Q2 results
CureVac BV press release (NASDAQ:CVAC): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program Shares +1.37% PM.Seeking Alpha • Jul 05
CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
German biotech CureVac N.V. (NASDAQ:CVAC) announced on Tuesday that the company filed a lawsuit in Germany over the infringement of certain intellectual property rights related to the COVID-19 vaccine developed by its local rival BioNTech (BNTX) and U.S. pharma giant Pfizer (PFE). The case was filed in the German Regional Court in Düsseldorf against BioNTech (BNTX) and two of its subsidiaries, CureVac (CVAC) said, noting it would fair compensation for the alleged violations. While CureVac (CVAC) has added ~1%, both BioNTech (BNTX) and Pfizer (PFE) have lost ~1% in the pre-market so far. However, the company said that it would not seek an injunction or resort to a legal action that could disrupt the production and sales of the blockbuster vaccine. The IP rights titled EP 1 857 122 B1, DE 20 2015 009 961 U1 relate to the development of mRNA, the compound behind the Pfizer (PFE)/ BioNTech (BNTX) COVID-19 vaccine.Article d’analyse • May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
Celebrations may be in order for CureVac N.V. ( NASDAQ:CVAC ) shareholders, with the analysts delivering a significant...Article d’analyse • Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Seeking Alpha • Sep 01
CureVac: Wait For Concrete News Before Investing
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.Article d’analyse • Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment CureVac gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 25 | 71 | 129 | 89 | 155 |
| 30 Jun 25 | 511 | 194 | 81 | 170 |
| 31 Mar 25 | 524 | 181 | 72 | 163 |
| 31 Dec 24 | 535 | 162 | 74 | 153 |
| 30 Sep 24 | 543 | 108 | 83 | 142 |
| 30 Jun 24 | 66 | -278 | 85 | 116 |
| 31 Mar 24 | 59 | -273 | 92 | 119 |
| 31 Dec 23 | 54 | -260 | 96 | 116 |
| 30 Sep 23 | 43 | -302 | 95 | 110 |
| 30 Jun 23 | 38 | -301 | 103 | 95 |
| 31 Mar 23 | 50 | -291 | 106 | 76 |
| 31 Dec 22 | 67 | -249 | 107 | 63 |
| 30 Sep 22 | 97 | -122 | 100 | 566 |
| 30 Jun 22 | 115 | -219 | 103 | 602 |
| 31 Mar 22 | 117 | -313 | 105 | 722 |
| 31 Dec 21 | 103 | -412 | 102 | 816 |
| 30 Sep 21 | 68 | -468 | 102 | 322 |
| 30 Jun 21 | 44 | -361 | 81 | 308 |
| 31 Mar 21 | 56 | -219 | 64 | 208 |
| 31 Dec 20 | 49 | -129 | 54 | 114 |
| 30 Sep 20 | 50 | -107 | 56 | 89 |
| 31 Mar 20 | 17 | -102 | 56 | 43 |
| 31 Dec 19 | 17 | -100 | 51 | 43 |
| 31 Dec 18 | 13 | -71 | 26 | 42 |
Des revenus de qualité: CVAC a un niveau élevé de bénéfices non monétaires.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de CVAC sont plus élevées que l'année dernière CVAC. sont plus élevées que l'année dernière (19.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CVAC est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 34.1% par an.
Accélération de la croissance: La croissance des bénéfices de CVAC au cours de l'année écoulée ( 19% ) est inférieure à sa moyenne sur 5 ans ( 34.1% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices CVAC au cours de l'année écoulée ( 19% ) n'a pas surpassé celle du secteur Biotechs 43%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de CVAC ( 14.8% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2025/12/17 09:10 |
| Cours de l'action en fin de journée | 2025/12/17 00:00 |
| Les revenus | 2025/09/30 |
| Revenus annuels | 2024/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CureVac N.V. est couverte par 4 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Eun Kyung Yang | Jefferies LLC |
| Roger Song | Jefferies LLC |